This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Vladimir Hachinski, MD, DSc(Med)

Arch Neurol. 1990;47(12):1354.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

We measure what we can, not necessarily what is most important. As Jonas demonstrates with persuasive clarity, quality of life and its loss may be more appropriate measures of outcome than conventional assessments of morbidity and mortality. Jonas concludes that, by his indexes, the possible benefits of aspirin in primary prevention remain unproven, and worries about the possible increased risk of stroke of individuals receiving aspirin. The latter is not only unproven, but unlikely.

The physicians reported to have suffered hemorrhagic strokes were few, younger than the usual age for stroke, and never had their diagnosis confirmed by computed tomography of the brain. Moreover, the experience with large studies with aspirin in prevention of myocardial infarction and stroke fail to identify an increased risk for stroke of any type.

Buring and colleagues acknowledge that uncertainties remain about the indications of aspirin in primary prevention, but invoke the evidence of aspirin's . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?